Your Complete Policy Management Partner
Everything your healthcare organization needs to confidently maintain accreditation compliance.
Robust document control and workflow management software solution
Simplify & automate policy access, review and approval across your organization
Web-based library of more than 18,000 customizable policy documents
Instantly access up-to-date policies, procedures & forms authored by MCN experts
Automated regulatory notification system of daily email or mobile alerts
Keep current with regulatory changes from more than a dozen federal regulatory bodies, including TJC & NIAHO
What Our Customers are Saying
MCN Healthcare has been indispensable to our accreditation compliance efforts. With Policy Manager, Policy Library and StayAlert!, we have peace of mind that our policies will always be up-to-date and easy to locate.
Beverly McKenzie, Compliance Programs Director, IASIS Healthcare
Helpful MCN Healthcare Resources
The former hospital technician, accused last year causing a multi-state outbreak of Hepatitis C infection has been sentenced to 39 years in prison. David Kwiatkowski stole syringes of the painkiller fentanyl from patients who were scheduled for surgery and injected himself causing them to become tainted with his own Hepatitis-C blood. He then refilled the tainted syringes with saline and replaced them for use during medical procedures.
Before his hire by the Exeter Hospital where he was eventually caught, Kwiatkowski had worked as a cardiac technologist in 18 hospitals in seven states, despite being fired several time over allegations of drug use and/or theft. According to reports, since his arrest last year 46 people in four states have been diagnosed with the same strain of hepatitis C Kwiatkowski carries: 32 patients were infected in New Hampshire, seven in Maryland, six in Kansas and one in Pennsylvania.
The details of this tragic case highlight the importance of good hiring practices as well as the need for comprehensive policies and procedures related to drug diversion. This case is an excellent opportunity to challenge your organization's policies against an actual incidence of drug diversion. Today's StayAlert includes example policies and procedures addressing hiring practices, background screening and pre-employment physicals. Also included are policies for management of controlled drugs.
The US Food and Drug Administration (FDA) is warning the public that the anti-seizure drug Onfi (clobazam) can cause rare but serious skin reactions that can result in permanent harm and death. FDA approved changes to the Onfi drug label and the patient Medication Guide to describe the risk of these serious skin reactions.
Onfi is a benzodiazepine medication used in combination with other medicines to treat seizures associated with a severe form of epilepsy called Lennox-Gastaut Syndrome.
The FDA recommends the following:
- Onfi can cause serious skin reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
- Patients should be closely monitored for signs or symptoms of SJS/TEN, especially during the first 8 weeks of treatment or when re-introducing therapy.
- Patients should be informed about the signs and symptoms of serious skin reactions and told that they should seek immediate medical treatment at the first appearance of a skin rash or any other sign of hypersensitivity.
- Onfi should be discontinued at the first sign of rash, unless the rash is clearly not drug-related. If signs or symptoms suggest a serious skin reaction, use of Onfi should not be resumed and alternative therapy should be considered.
- When assessing patients with potentially drug-induced skin reactions, Onfi should be considered as a possible cause, along with other drugs already known to have such an association. Some other antiepileptic drugs can also cause serious skin reactions, and health care professionals should consider this when changing from one antiepileptic drug to another.
- Health care professionals should encourage patients to read the Medication Guide they receive with every filled prescription.
- Adverse events involving Onfi should be reported to the FDA MedWatch program, using the information in the Contact FDA box at the bottom of this page.
Read the MedWatch safety alert, including links to the FDA Drug Safety Communication and prescribing information (label) at the link below.
Abbott Issues Voluntary Recall of Certain FreeStyleÂ® and FreeStyle LiteÂ® Blood Glucose Test Strips in the United States
Abbott has announced it is initiating a voluntary recall of 20 lots of FreeStyle® and FreeStyle Lite® Blood Glucose Test Strips in the United States.
These lots of test strips may produce erroneously low blood glucose results when used with both "FreeStyle® Blood Glucose Meter" and "FreeStyle® Flash Blood Glucose Meter" [neither of which have been in production since 2010], as well as the OmniPod® Insulin Management System. When the test strips are used with the newer FreeStyle brand meters including FreeStyle® Freedom Blood Glucose Meter, FreeStyle Lite® Blood Glucose Meter* and FreeStyle Freedom® Lite Blood Glucose Meter*, the blood glucose test results are not affected. Testing with the FreeStyle InsuLinx® Blood Glucose Meter is not affected by this action, as FreeStyle InsuLinx Blood Glucose Meter uses FreeStyle InsuLinx test strips.
The affected test strips are from lots that hold expiration dates from between May 2014 and March 2015, and can be identified as follows:
Abbott is notifying healthcare professionals, pharmacies, distributors and customers about the recall; customers affected by this action are instructed to call Abbott's diabetes care customer service at 1-888-736-9869 for a replacement of the affected test strips at no charge.
Featured Policy Library Manuals
MCN Healthcare’s HIPAA Guidelines Policy and Procedure Manual provides policies and procedures addressing the HIPAA Privacy Rule, the HIPAA Security Rule, Notification of Breach of Protected Health Information (HITECH), and Transactions and Code Sets as mandated by the federal government. Policies and procedures include the changes covered in the Omnibus Final Rule, January 2013.Read more »
The Medical Office Policy and Procedure Manual is cross referenced to Joint Commission standards for Ambulatory Care and Primary Care Medical Homes and NCQA standards for Patient Centered Medical Homes. This manual includes policies that meet OSHA requirements for safety and infection control, Human Resources policies and Medical Office Compliance Plan and much more!Read more »
Be sure your organization is in compliance with Joint Commission’s National Patient Safety Goals with MCN's quick, easy-to-use and proven reference guide that addresses each NPSG and associated Elements of Performance. This comprehensive resource tool includes over 140 policies, procedures, forms and implementation tools. Includes policies and procedures for the NEW NPSG.06.01.01!Read more »